



---

[Investor Relations](#)

---

[Press Releases](#)

---

[Investor Presentations](#)

---

[Corporate Governance](#)

---

[Financials & Filings](#)

---

[Stock Information](#)

---

[Investor FAQs](#)

---

[Contact Us](#)

---

2/5/14

## Trevena Announces Closing of Initial Public Offering

Trevena, Inc. (NASDAQ: TRVN), a clinical stage pharmaceutical company involved in the discovery and development of G protein coupled receptor (GPCR) biased ligands, today announced the closing of its initial public offering of 9,250,000 shares of common stock at an initial public offering price of \$7.00 per share.

Barclays Capital Inc. and Jefferies LLC acted as joint book-running managers for the offering. Canaccord Genuity Inc., JMP Securities LLC and Needham & Company, LLC acted as co-managers.

A registration statement relating to these securities was declared effective by the Securities and Exchange Commission on January 30, 2014.

The offering was made only by means of a prospectus. A copy of the final prospectus may be obtained from Barclays Capital Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, by email at [Barclaysprospectus@broadridge.com](mailto:Barclaysprospectus@broadridge.com) or by phone at 888-603-5847 or Jefferies LLC, Equity Syndicate Prospectus Department, 520 Madison Avenue, 12th Floor, New York, NY 10022, by email at [Prospectus\\_Department@Jefferies.com](mailto:Prospectus_Department@Jefferies.com) or by phone at 877-547-6340.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

### About Trevena

Trevena, Inc. is a clinical stage biopharmaceutical company that discovers, develops and intends to commercialize therapeutics that use a novel approach to target G protein coupled receptors, or GPCRs. Using its proprietary product platform, Trevena has identified and advanced three differentiated product candidates into the clinic – TRV027 to treat acute heart failure, TRV130 to treat moderate to severe acute pain intravenously, and TRV734 to treat moderate to severe acute and chronic pain orally. Trevena also plans to advance additional product candidates, including a preclinical program focused on central nervous system indications.

### Contacts

#### Investor Contacts:

Trevena, Inc.  
Roberto Cuca, 610-354-8840 x224  
Senior vice president and chief financial officer  
[rcuca@trevenainc.com](mailto:rcuca@trevenainc.com)

Argot Partners  
Andrea Rabney, 212-600-1902  
President and chief executive officer  
[andrea@argotpartners.com](mailto:andrea@argotpartners.com)

#### Media Contact:

Argot Partners  
Eliza Schleichstein, 917-763-8106  
[eliza@argotpartners.com](mailto:eliza@argotpartners.com)

**About Trevena**

Founding of Trevena  
Management  
Board of Directors  
Scientific Advisory Board  
Partners  
Careers

**Products**

TRV027  
TRV130  
TRV734  
Delta Opioid

**Investors**

Press Releases  
Investor Presentations  
Corporate Governance  
Financials & Filings  
Stock Information  
Investor FAQs  
Contact Us

**Publications**

TRV027  
TRV130  
Biased Ligand